More News

17 June 2019

Voyager Therapeutics Announces Restructured Gene Therapy Relationship with Sanofi Genzyme and Portfolio Update

17 June 2019

Intralytix, the Eliava Foundation and Ferring Pharmaceuticals Sign Joint Collaboration Agreement for Reproductive Medicine and Women’s Health Initiatives

17 June 2019

Pfizer to Acquire Array BioPharma

13 June 2019

AbCellera Announces Therapeutic Antibody Discovery Collaboration with Gilead in Infectious Disease

12 June 2019

Sobi acquires emapalumab and related assets

11 June 2019

Genmab Signs Agreement with Janssen for Next-Generation CD38 Antibody, HexaBody®-CD38

11 June 2019

BiomX Licenses Novel Targets for Liver Disease Phage Therapy Program From JSR Corporation in Japan

10 June 2019

Merck to Acquire Tilos Therapeutics

7 June 2019

Vertex Expands into New Disease Areas and Enhances Gene Editing Capabilities Through Expanded Collaboration with CRISPR Therapeutics and Acquisition of Exonics Therapeutics

3 June 2019

Vical and Brickell Announce Merger Agreement

31 May 2019

ASLAN Pharmaceuticals Acquires Full Global Commercial Rights for ASLAN004 From CSL

30 May 2019

Amicus Therapeutics and the University of Pennsylvania Announce Major Expansion of Gene Therapy Collaboration

30 May 2019

Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonists

29 May 2019

Orchard Therapeutics, Fondazione Telethon and Ospedale San Raffaele Announce Exclusive Worldwide License Agreement for the Treatment of MPS-I

29 May 2019

Lilly Announces Licensing Agreement for Non-Opioid Pain Asset from Centrexion Therapeutics

29 May 2019

Ziopharm Oncology Announces Exclusive License with National Cancer Institute to Identify and Use T-Cell Receptors Targeting Neoantigens for Cancer with Sleeping Beauty Platform

28 May 2019

Sensorion Announces the Signature of a Partnership Framework Agreement with Institut Pasteur on Gene Therapy Programs Targeting Hearing Loss

24 May 2019

FDA Approves the NovoTTF-100LTM System in Combination with Chemotherapy for the Treatment of Malignant Pleural Mesothelioma NovoTTF-100L, a Tumor Treating Fields delivery system, is the first FDA-approved mesothelioma treatment in more than 15 years In

21 May 2019

Evotec jump-starts biologics with acquisition of Just Biotherapeutics

21 May 2019

Merck to Acquire Peloton Therapeutics, Bolstering Oncology Pipeline

21 May 2019

CureVac Enters into an Exclusive Sponsored Research Agreement for Discovery Research in mRNA-based Eye Therapy Candidates with the Schepens Eye Research Institute, Harvard Medical School and the Massachusetts Eye and Ear Infirmary

21 May 2019

Santhera Starts Collaboration in Gene Therapy Research for Congenital Muscular Dystrophy with the Biozentrum, University of Basel, Co-Financed by Innosuisse

18 May 2019

Ligand Licenses VER250840 to Cumulus Oncology

16 May 2019

Genocea Announces Research Collaboration with Iovance to Explore Development of Neoantigen-Targeted TIL (Tumor-Infiltrating Lymphocyte) Products

16 May 2019

HDL Therapeutics Announces Positive Data From Registration Trial of PDS-2™ System in Homozygous Familial Hypercholesterolemia

16 May 2019

ASC Therapeutics Licenses Critical Technologies for Hemophilia A Gene Therapy from Expression Therapeutics

16 May 2019

Parvus Therapeutics Enters into Worldwide Collaboration and License Agreement with Genentech to Develop Navacim™ Therapeutics for the Treatment of Autoimmune Diseases

16 May 2019

Exelixis and Iconic Therapeutics Enter into Exclusive Option and License Agreement for Novel Antibody-Drug Conjugate Program

15 May 2019

Scintomics and 1717 Life Science Ventures Team up in the Joint Venture PENTIXAPHARM to Develop CXCR4-Targeted Theranostics

15 May 2019

Vertex and Kymera Therapeutics Establish Strategic Collaboration to Discover and Develop Targeted Protein Degradation Medicines for Serious Diseases

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Pembrolizumab (Keytruda) Biosimilar Antibody Pipeline Review

TL1A Inhibitor Pipeline Review

2020 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Degrader-Antibody Conjugates 2024: A Landscape Analysis of Stakeholders, Technologies, Pipeline and Partnering from an Industry Perspective

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

CD47 and SIRP-alpha Targeted Immunotherapy Pipeline Review

PSMA-Targeted Therapy Pipeline Review

TROP-2-Targeted Immunotherapy Pipeline Review

CD73 Inhibitor Pipeline Review

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective